Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. (Q47788877)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 June 2017

Language	Label	Description	Also known as
English	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.	scientific article published on 22 June 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Richard A Hubner

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

author name string

Tim Meyer

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Richard Fox

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Paul J Ross

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Martin W James

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Richard Sturgess

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Clive Stubbs

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Deborah D Stocken

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Lucy Wall

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Anthony Watkinson

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Nigel Hacking

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

T R Jeffry Evans

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Peter Collins

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Philip J Johnson

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Daniel H Palmer

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

David Cunningham

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

publication date

23 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

The lancet. Gastroenterology & hepatology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

565-575

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A general inefficacy interim monitoring rule for randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous analysis of quality of life and survival data.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS2468-1253%2817%2930156-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2468-1253(17)30156-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28648803%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47788877&oldid=1501168711"